Hendrickson RG
From a patient perspective, a few things stand out to me: Not everyone wants to be on injections for years
However, as clinicians celebrate these advances, a Read More Why Early Combination Therapy Is Gaining Momentum in Young-Onset Type 2 Diabetes May 19, 2026 Articles, Blood Glucose Control, Devices, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Metformin Therapy Center, SGLT-2 Therapy Center, Therapies, Type 2 Diabetes, Type 2 Diabetes 1,711 views Young adults diagnosed with type 2 diabetes early in life often face a more aggressive disease course than older adults
Eli Lilly is leading with a phase II trial initiated in early 2025 to evaluate mazdutide, a GLP-1/GIP dual agonist, in participants with AUD
doi:10.1111/cns.70053 93
It defines psychoactive substances as anything capable of producing a psychoactive effect in the user, meaning it stimulates or depresses the central nervous system, affecting the users mental functioning or emotional state
